Scilex Holding Co 8-K Filing

FAQ

Key Financial Figures

• $0.0001 — h registered) Common Stock, par value $0.0001 per share SCLX The Nasdaq Stock Mar
• $402.50 — mon stock, each at an exercise price of $402.50 SCLXW The Nasdaq Stock Market LLC
• $0.01 — of the Company at an exercise price of $0.01 per share (the "Penny Warrants"). Als
• $27,000,000 — se") for an aggregate purchase price of $27,000,000 (the "Warrant Repurchase Amount"), subj
• $1,500,000 — ny agreed to pay Oramed an aggregate of $1,500,000. On December 30, 2025, the Company co
• $14,000,000 — Warrants, having an aggregate price of $14,000,000, after having completed the first tranc
• $13,000,000 — t tranche of the Warrant Repurchase for $13,000,000 in September 2025. The information in

Filing Documents

• sclx-20251230.htm (8-K) — 46KB
• 0001193125-25-336947.txt ( ) — 204KB
• sclx-20251230.xsd (EX-101.SCH) — 62KB
• sclx-20251230_htm.xml (XML) — 6KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure As previously disclosed, Scilex Holding Company (the "Company") issued to Oramed Pharmaceuticals Inc., a Delaware corporation ("Oramed"), on September 21, 2023, warrants to purchase up to an aggregate of 6,500,000 shares of common stock, par value $0.0001 per share, of the Company at an exercise price of $0.01 per share (the "Penny Warrants"). Also as previously disclosed, on July 22, 2025, the Company entered into an Option Agreement for the Repurchase of Warrants with Oramed, pursuant to which, among other things, Oramed granted an option (the "Option") to the Company to repurchase the Penny Warrants in two tranches (the "Warrant Repurchase") for an aggregate purchase price of $27,000,000 (the "Warrant Repurchase Amount"), subject to the terms and conditions set forth therein. In consideration of the Option, the Company agreed to pay Oramed an aggregate of $1,500,000. On December 30, 2025, the Company completed the exercise in full of the Option by paying off the remaining Warrant Repurchase Amount for the second tranche of Penny Warrants, having an aggregate price of $14,000,000, after having completed the first tranche of the Warrant Repurchase for $13,000,000 in September 2025. The information in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SCILEX HOLDING COMPANY By: /s/ Henry Ji Name: Henry Ji Date: December 30, 2025 Title: Chief Executive Officer & President 3

View Full Filing

View this 8-K filing on SEC EDGAR